{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:24:20Z","timestamp":1790987060822,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/bjc.2012.349","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T22:57:38Z","timestamp":1346799458000},"page":"901-903","source":"Crossref","is-referenced-by-count":6,"title":["Why are patients with chronic myeloid leukaemia (non-)adherent?"],"prefix":"10.1038","volume":"107","author":[{"given":"I","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,4]]},"reference":[{"issue":"22","key":"BFbjc2012349_CR1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (2009) International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnoses chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114 (22): 1126 (abstract)","journal-title":"Blood"},{"key":"BFbjc2012349_CR2","first-page":"854","volume":"17","author":"S De Geest","year":"1998","unstructured":"De Geest S, Abraham I, Moons P, Vandeputte M, Van Cleemput J, Evers G, Danene W, Vanhaecke J (1998) Late acute rejections and subclinical noncompliance with cyclosporine therapy in heart transplant patients. J Heart Lung Transplant 17: 854\u2013863","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"BFbjc2012349_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","volume":"42","author":"MR DiMatteo","year":"2004","unstructured":"DiMatteo MR (2004a) Variations in patients\u2019 adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42 (3): 200\u2013209","journal-title":"Med Care"},{"issue":"2","key":"BFbjc2012349_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/0278-6133.23.2.207","volume":"23","author":"MR DiMatteo","year":"2004","unstructured":"DiMatteo MR (2004b) Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 23 (2): 207\u2013218","journal-title":"Health Psychol"},{"issue":"23","key":"BFbjc2012349_CR5","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Bl Powell, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepher J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, for the IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (23): 2408\u20132417","journal-title":"N Engl J Med"},{"key":"BFbjc2012349_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F (2012) Investigating factors associated with adherence behavior in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107: 904\u2013909","journal-title":"Br J Cancer"},{"issue":"5","key":"BFbjc2012349_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients\u2019 reason for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35 (5): 626\u2013630","journal-title":"Leuk Res"},{"issue":"7","key":"BFbjc2012349_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D\u2019Emilio A, Stagna F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jan E, Reiffers J, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Nat Cancer Inst 103 (7): 553\u2013561","journal-title":"J Nat Cancer Inst"},{"issue":"6","key":"BFbjc2012349_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86 (6): 471\u2013474","journal-title":"Am J Hematol"},{"issue":"3","key":"BFbjc2012349_CR10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","volume":"111","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O\u2019Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM (2008) Favorable long-term follow-up results after 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1 treatment. Blood 111 (3): 1039\u20131043","journal-title":"Blood"},{"issue":"14","key":"BFbjc2012349_CR11","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main the reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117 (14): 3733\u20133736","journal-title":"Blood"},{"issue":"5","key":"BFbjc2012349_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","volume":"91","author":"S J\u00f6nsson","year":"2012","unstructured":"J\u00f6nsson S, Olsson B, S\u00f6derberg J, Wadenvik H (2012) Good adherence to imatinib therapy among patients with chronic myeloid leukemia \u2013 a single center observational study. Ann Hematol 91 (5): 679\u2013685","journal-title":"Ann Hematol"},{"issue":"14","key":"BFbjc2012349_CR13","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28 (14): 2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"22","key":"BFbjc2012349_CR14","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zach\u00e9e P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113 (22): 5401\u20135411","journal-title":"Blood"},{"issue":"11","key":"BFbjc2012349_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepher J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, For the IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (11): 994\u20131004","journal-title":"N Engl J Med"},{"issue":"9","key":"BFbjc2012349_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","volume":"94","author":"AH Partridge","year":"2002","unstructured":"Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. J Nat Cancer Inst 94 (9): 652\u2013661","journal-title":"J Nat Cancer Inst"},{"issue":"1","key":"BFbjc2012349_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59 (1): 56\u201366","journal-title":"CA Cancer J Clin"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2012349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012349","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:09:46Z","timestamp":1684415386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2012349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFbjc2012349"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.349","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}